7th Dermatology Drug Development Summit Europe
The 7th Dermatology Drug Development Summit Europe is a premier three-day industry event designed for senior leaders, clinical scientists, regulatory experts and commercial strategists shaping the future of dermatological therapeutics. Positioned at a pivotal time in dermatology R&D, this summit focuses on accelerating late-stage programmes, navigating European regulatory and access challenges, and forging strategic partnerships to bring differentiated drugs to patients across common and rare skin conditions.
Why Attend:
- Clinical & Regulatory Insight: Learn from leading dermatology teams about strategies to generate robust clinical signals in high-placebo indications and design feasible European trial programmes.
- Access & Market Challenges: Explore approaches to address pricing pressures, health technology assessment (HTA) scrutiny, and the evolving gap between market authorization and patient access in Europe.
- Emerging Modalities: Discuss the latest in advanced modalities—including small molecules, biologics, gene therapies, oligonucleotides, and targeted topicals—moving into Phase II–IV.
- Peer Exchange & Networking: The summit encourages candid peer-to-peer exchange with over 60+ senior attendees from pharma and biotech, fostering collaboration and benchmarking strategies.
Programme Highlights:
- Interactive Single-Track Sessions with deep dives into clinical design, regulatory readiness, trial execution, and payer evidence preparation.
- Pre-Conference Workshops: Two focused sessions to sharpen tactical skills ahead of the main programme.
- Networking Time: Over six hours of structured networking to build new relationships and strengthen existing collaborations.
Expert Speaker Faculty:
The summit features an international roster of industry leaders, including heads of clinical development, immunology research, business development, and medical affairs from major pharmaceutical and biotechnology organisations such as Sanofi, Merck & Co., Pierre Fabre, Boehringer Ingelheim, Glenmark Pharmaceuticals and others.
Who Should Attend:
This event is ideal for professionals involved in late-stage dermatology drug development, including clinical operations, regulatory affairs, medical affairs, commercial strategy, business development, and partnering functions within pharmaceutical and biotech companies.
Whether you’re looking to benchmark late-stage development approaches, understand regulatory and payer landscapes in Europe, or deepen engagement with key dermatology innovators, this summit offers a targeted, high-value platform to advance your programme’s clinical and commercial success.
Registration & More:
Early registration discounts are available, and full event details including agenda, speaker list and sponsorship opportunities can be accessed through the official event guide.
